HEALTH-SOVEREIGNTY & MEDTECH DESK · DISPATCH
The European Investment Bank signed a €20 million, 20-year equity-type loan with PRECISIS, a German medical technology company, backed by the European Union's InvestEU guarantee. The signed facility funds continued clinical development and market access for EASEE, a minimally invasive brain-pacemaker system for drug-resistant focal epilepsy. The bank's own record gives the reason for the structure plainly: the financing was arranged with capitalized interest because traditional long-term debt was not available for a device category this capital-intensive.
That sentence is the whole transaction. Capitalized interest means the borrower pays no cash coupon while it burns capital through clinical work and commercial launch—the interest rolls into principal and comes due once, much later. The lender therefore carries something close to equity risk while remaining, formally, a lender. It is quasi-equity wearing a loan's paperwork, and a commercial bank cannot write it, which is why the InvestEU guarantee sits underneath. The public balance sheet absorbs the first loss that makes the instrument possible at all.
The tenor is the other tell. Twenty years is longer than the fund life of essentially any venture vehicle that would otherwise finance a Class III implantable at this stage, and it is far longer than the horizon over which such a company is usually pushed toward a trade sale. Patient capital is a phrase used loosely; a twenty-year amortization with deferred interest is what it looks like when it is real. The instrument does not merely price the risk differently. It changes how long the company can stay independent while it works.
Where this sits on the chain matters, and it is early. The facility is signed and the money is for clinical development and market access—not for manufacturing capacity, not for a plant, not for volume. Nothing here is installed production. What is being financed is survival through the regulatory-and-adoption valley that strands more European device companies than any capital shortage does: approvals, reimbursement decisions, and the slow grind of clinical uptake in national health systems.
The logic is capital formation rather than reshoring. Nobody is displacing an incumbent supplier or writing a domestic-content condition into a hospital tender. Brussels is keeping a neuromodulation company European through the years when its ownership would otherwise be decided by whoever could fund the gap—a quieter form of health-technology sovereignty than a stockpile contract, and a more durable one.
A guarantee, a deferred coupon and a twenty-year clock are not a subsidy to a single firm. They are Europe deciding that the place its device industry gets lost is the balance sheet, and legislating a lender into that gap—capital statecraft with the interest switched off.
— Capital Statecraft Intelligence · Health-Sovereignty & MedTech Desk
Primary source(s): European Investment Bank project record, 1 July 2025